{
    "clinical_study": {
        "@rank": "18499", 
        "acronym": "MEDEA", 
        "arm_group": [
            {
                "arm_group_label": "metoclopramide", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "dexamethason", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "palonosetron", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and\n      palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard\n      to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced\n      by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy\n      (MEC)."
        }, 
        "brief_title": "MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy", 
        "condition": "Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has been diagnosed with histologically or cytologically confirmed solid\n             cancer\n\n          -  Starting with first cycle of chemotherapy of moderate emetogenic risk, which does not\n             include a combination of anthracycline plus cyclophosphamide\n\n          -  Age \u2265 18\n\n          -  WHO \u2264 1\n\n          -  Patient is able to understand and speak Dutch\n\n        Exclusion Criteria:\n\n          -  Patient with nausea and/or vomiting in 48 hours before start of chemotherapy\n             treatment\n\n          -  Patient submitted to concomitant radiotherapy or submitted to radiotherapy 15 days\n             before start of chemotherapy or planned to receive radiotherapy during 8 days after\n             administration of chemotherapy\n\n          -  Patient with concomitant severe comorbidy, such as: o Intestinal obstruction o Active\n             peptic ulcer o Hypercalcemia o Uncontrolled diabetes mellitus o Pheochromocytoma o\n             Tardive dyskinesia o Epilepsia o Active infective diseases o Brain - or\n             leptomeningeal metastases o Psychiatrical disorders o Parkinsonism\n\n          -  Current use of corticosteroids (similar to prednisone \u2265 10 milligrams per day)\n\n          -  Current alcohol abuse\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135510", 
            "org_study_id": "2011/366"
        }, 
        "intervention": [
            {
                "arm_group_label": "metoclopramide", 
                "intervention_name": "metoclopramide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "dexamethason", 
                "intervention_name": "dexamethason", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "palonosetron", 
                "intervention_name": "palonosetron", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Metoclopramide", 
                "Dexamethasone 21-phosphate", 
                "BB 1101", 
                "Emetics", 
                "Palonosetron"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "S.C.S. Tromp-van Driel", 
                    "phone": "(0223) 69 69 69"
                }, 
                "facility": {
                    "address": {
                        "city": "Den Helder", 
                        "country": "Netherlands", 
                        "state": "Noord Holland", 
                        "zip": "1782 GZ"
                    }, 
                    "name": "Gemini Ziekenhuis"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "H.P. van den Berg", 
                    "phone": "088 753 17 53"
                }, 
                "facility": {
                    "address": {
                        "city": "Hilversum", 
                        "country": "Netherlands", 
                        "state": "Noord Holland", 
                        "zip": "1213 XZ"
                    }, 
                    "name": "Tergooiziekenhuizen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "S Vrijaldenhoven", 
                    "phone": "(072) 548 2870"
                }, 
                "facility": {
                    "address": {
                        "city": "Alkmaar", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland", 
                        "zip": "1815 JD"
                    }, 
                    "name": "Medisch Centrum Alkmaar"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "A. van Zweeden", 
                    "phone": "(020) 755 7000"
                }, 
                "facility": {
                    "address": {
                        "city": "Amstelveen", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland", 
                        "zip": "1186 AM"
                    }, 
                    "name": "Ziekenhuis Amstelland"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "J Brakenhoff", 
                    "phone": "0299 457 457"
                }, 
                "facility": {
                    "address": {
                        "city": "Purmerend", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland", 
                        "zip": "1441 RN"
                    }, 
                    "name": "Waterland Ziekenhuis"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "A. van Bochove", 
                    "phone": "(075) 650 29 11"
                }, 
                "facility": {
                    "address": {
                        "city": "Zaandam", 
                        "country": "Netherlands", 
                        "state": "Noord-Holland", 
                        "zip": "1502 DV"
                    }, 
                    "name": "De Heel - Zaans Medisch Centrum"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary efficacy endpoint: the proportion of patients reporting complete response during the overall 24 to 160 hours after initiation of the first cycle of moderately emetogenic chemotherapeutic (MEC). Complete response is defined as no vomiting and nausea and no use of rescue medication. A diary will be used to document the date and time of any emetic episodes and use of rescue medication, as well as daily nausea ratings.", 
                "measure": "efficacy", 
                "time_frame": "24 to 160 hours"
            }, 
            {
                "description": "Primary tolerability endpoint: the proportion of patients with minimal or no antiemetic therapy-related side effects according to the Dexamethasone Symptom Questionnaire (DSQ) questionnaire, the Abnormal Involuntary Movement Scale (AIMS) and Aprepitant questionnaire during the first cycle of moderately emetogenic chemotherapeutic (MEC).", 
                "measure": "tolerability", 
                "time_frame": "24 to 160 hours"
            }, 
            {
                "description": "Primary cost-effectiveness endpoint: total antiemetic medication costs per treatment regimen during the first cycle of Moderately Emetogenic Chemotherapy (MEC). A diary will be used to document the use of antiemetics and rescue medication. Total medication costs will be calculated from this.", 
                "measure": "cost-effectiveness", 
                "time_frame": "24 to 160 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135510"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VU University Medical Center", 
            "investigator_full_name": "H.M.W. Verheul", 
            "investigator_title": "Head Department Medical Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "VU University Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Medisch Centrum Alkmaar", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "De Heel, Zaans Medisch Centrum", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Waterland Ziekenhuis", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tergooiziekenhuizen locatie Hilversum", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ziekenhuis Amstelland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gemini Ziekenhuis", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "VU University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}